Novel Approaches and Challenges in Advancing Molecules into the Clinic

The Oncology Stream at PEGS Boston 2025 brings together three cutting-edge events focused on revolutionizing cancer treatment. The Antibodies for Cancer Therapy conference explores innovative approaches and optimization of antibody-based treatments, as well as lessons learned in mitigating risks and maximizing patient outcomes. The Emerging Targets for Oncology & Beyond conference delves into novel target discovery, and development of new approaches for targeting the tumor microenvironment; while the Driving Clinical Success in Antibody-Drug Conjugates conference showcases advancements in ADC design with novel payloads, MOAs and engineering strategies to enhance efficacy and increase therapeutic window. Collectively, these conferences present the exciting promise of a next wave in personalized medicine and targeted therapies.

Conferences Include:

May 12-13

Antibodies for Cancer Therapy

May 13-14

Emerging Targets for Oncology and Beyond

May 15-16

Driving Clinical Success in Antibody-Drug Conjugates

Keynote and Featured Speakers:

Nonclinical Immunogenicity Risk Assessment and Mitigation for Bispecific Antibodies
Paul J. Carter, PhD, Genentech Fellow, Antibody Engineering, Genentech

Advancing TCRm Antibody Therapy: Insights and Lessons Learned for Maximizing Patient Outcomes
Scott Chunhua Shi, PhD, Associate Director Institute & Head of Biological Discovery, ORBIT Therapeutic Discovery, MD Anderson Cancer Center

GlycoRNA Biology in Health and Disease
Ryan A. Flynn, PhD, Assistant Professor, Stem Cell and Regenerative Biology, Boston Children's Hospital

Protein Engineering Strategies to Improve the Efficacy of Antibody-Drug Conjugates
Greg M. Thurber, PhD, Associate Professor, Chemical Engineering & Biomedical Engineering, University of Michigan

2025 PROGRAMS

View By:

• Display of Biologics
• Engineering Antibodies
• Machine Learning for Protein Engineering

• Antibodies for Cancer Therapy
• Emerging Targets for Oncology & Beyond
• Driving Clinical Success in Antibody-Drug Conjugates

• TS: Intro to Multispecific Antibodies
• Advancing Multispecific Antibodies
• Engineering Bispecific and Multifunctional Antibodies

• Advances in Immunotherapy
• Engineering Cell Therapies
• Next-Generation Immunotherapies

• Difficult-to-Express Proteins
• Optimizing Protein Expression
• Maximizing Protein Production Workflows

• ML and Digital Integration in Biotherapeutic Analytics
• Biophysical Methods
• Characterization for Novel Biotherapeutics

• TS: Intro to Immunogenicity
• Predicting Immunogenicity with AI/ML Tools
• TS: Bioassay Development and Analysis

• Biologics for Immunology Indications
• Radiopharmaceutical Therapies
• Next-Generation Immunotherapies

• ML and Digital Integration in Biotherapeutic Analytics
• Predicting Immunogenicity with AI/ML Tools
• Machine Learning for Protein Engineering